Today Getinge announced commercial availability of the iCast covered stent system in the United States for the treatment of iliac arterial occlusive disease. In March 2023, the iCast covered stent received premarket approval from the U.S. Food and Drug Administration (FDA) for the treatment of iliac arterial occlusive disease. Lower extremity peripheral artery disease (PAD) is estimated to affect approximately 8.5 million people in the U.S. per year [[]][,[]].
Getinge Announces U.S. Commercial Availability of iCast Covered Stent System for Treatment of Iliac Arterial Occlusive Disease
“Getinge’s sales rose organically by 5.7% in the quarter,” says Mattias Perjos, President & CEO at Getinge. “Most of the operations in Acute Care Therapies performed positively. Sales in Life Science were unchanged and Surgical Workflows grew in all product categories and regions. The order intake declined organically by a total of 1.9% in the quarter, which was exclusively linked to Acute Care Therapies.”
Getinge Interim Report July - September 2023: Higher sales, gradually strengthened margins and stable cash flows
Getinge announced today that it has acquired 100 percent of the shares in US-based Healthmark Industries Co. Inc., a leading provider of innovative instrument care and infection control consumables, for approximately USD 320 M. This strategic step enhances Getinge’s presence within sterile reprocessing in the US and facilitates a global expansion for Healthmark.
Getinge acquires Healthmark Industries Co. Inc.
The SBTi’s Target Validation Team today announces that Getinge’s near and long-term targets are aligned with the SBTi's 1.5°C mitigation pathways for reaching net-zero by 2050 or sooner. By this, Getinge commits to reach net-zero greenhouse gas emissions across the value chain by 2050 from a 2021 base year.
Getinge’s net-zero targets approved by the SBTi
Are you looking for
Diverse picture format made available for press article purpose
All you need to know about Getinge a one glance
Urgent Medical Device Correction
Voluntary Urgent Medical Device Field Correction for the CARDIOSAVE intra-aortic balloon pump (IABP)
Don't miss anything
Click on the icons and follow us!